BioSpace News Archive

Drug Development

Alnylam Aces Phase III Cardio Trial, Eyes Label Expansion for RNAi Therapy

Alnylam’s Amvuttra reduced the risk of all-cause death or recurrent cardiovascular events by at least 28% in patients with transthyretin amyloidosis with cardiomyopathy, the company announced Monday.

June 24, 2024
·
3 min read
·
Tristan Manalac
Drug Development

Novo’s Wegovy Shows Stronger Weight-Loss Effects in Women Than Men: Study

Novo Nordisk’s Wegovy elicited greater weight loss in women than in men with heart failure, according to data presented Sunday at the American Diabetes Association’s 2024 Scientific Sessions.

June 24, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass

Altimmune’s obesity candidate pemvidutide strongly preserved lean muscle mass, with fat accounting for more than 78% of weight lost by participants in a Phase II study.

June 24, 2024
·
2 min read
·
Tristan Manalac
Drug Development

G1 Therapeutics Fails Late-Stage Breast Cancer Trial, Plans ‘Targeted’ Headcount Reductions

G1 Therapeutics on Monday reported Phase III study results showing its drug Cosela did not demonstrate a statistically significant effect in overall survival in triple-negative breast cancer patients.

June 24, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win

Data showed that Eli Lilly’s Zepbound could resolve obstructive sleep apnea in at least 43% of patients, solidifying the pharma’s case for label expansion.

June 24, 2024
·
2 min read
·
Tristan Manalac
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good

Continuing investment in basic infectious disease research and pandemic preparedness infrastructure isn’t just about being ready for the next pandemic—it’s also a smart business move.

June 24, 2024
·
6 min read
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association’s 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU) today announced data from two late-breaker presentations at the American Diabetes Association’s 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.

June 24, 2024
·
11 min read
Drug Development

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer.

June 24, 2024
·
6 min read
Business

Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio

Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.

June 24, 2024
·
3 min read
BioMidwest

University of Cincinnati Cancer Center Launches Nation’s Most Comprehensive Blood Cancer Healing Center

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

June 24, 2024
·
4 min read